2025-10-03 - Analysis Report
Okay, let's analyze Merck & Co Inc (MRK) based on the provided data.

## Merck & Co Inc (MRK) Analysis

**Company Overview:** Merck & Co Inc (MRK) is a global pharmaceutical company that develops and provides health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products.

**1. Performance vs. S&P 500 (VOO):**

*   **MRK Cumulative Return:** -4.94%
*   **VOO Cumulative Return:** 97.56%
*   **Deviation (MRK - VOO):** -102.5%
*   **Deviation Range:** Max: 23.9%, Min: -103.9%
*   **Relative Deviation:** 1.1%

**Analysis:** MRK has significantly underperformed the S&P 500 (VOO).  The relative deviation of 1.1% indicates that the current deviation is near the lower end of its historical range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
|------------|---------|-------|---------|-------|--------|
| 2015-2017  | 1.0%    | 68.5% | -28.0%  | 0.0   | 134.1  |
| 2016-2018  | 36.0%   | 69.8% | 21.0%   | -0.0  | 182.1  |
| 2017-2019  | 40.0%   | 69.8% | 18.0%   | 0.3   | 216.7  |
| 2018-2020  | 16.0%   | 79.6% | -8.0%   | 0.3   | 194.9  |
| 2019-2021  | 2.0%    | 79.6% | -44.0%  | 0.7   | 191.4  |
| 2020-2022  | 15.0%   | 79.6% | 16.0%   | 0.7   | 277.0  |
| 2021-2023  | 33.0%   | 79.6% | 31.0%   | 0.3   | 272.2  |
| 2022-2024  | -4.0%   | 79.6% | -25.0%  | 0.2   | 248.4  |
| 2023-2025  | -54.0%  | 71.5% | -116.0% | 1.6   | 200.2  |

**Analysis:**

*   **CAGR:**  The Compounded Annual Growth Rate shows significant fluctuation, with recent years showing negative growth.
*   **MDD:** Maximum Drawdown is consistently high, indicating substantial potential for losses.
*   **Alpha:** Alpha is primarily negative, especially in recent periods, which means MRK has underperformed relative to its risk (Beta).
*   **Beta:** Beta values are generally low, suggesting the stock is less volatile than the overall market (S&P 500).  The most recent Beta of 1.6 is very high, suggesting a high correlation with the market recently.
*   **Capitalization:**  The capitalization value shows the company's market value.

**2. Recent Price Movements:**

*   **Current Price:** 80.195
*   **Last Market Price:** 89.51 (Previous Close: 90.13, Change: -0.69)
*   **5-day Moving Average:** 79.163
*   **20-day Moving Average:** 82.039
*   **60-day Moving Average:** 82.3822

**Analysis:** The current price is below the 20-day and 60-day moving averages, indicating a potential downward trend. The price decrease in the Last Market data suggests recent selling pressure.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 32.84 (Approaching Oversold)
*   **PPO:** -0.498
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (206 shares - Very Safe - MRI:0.90)
*   **Delta Previous Relative Divergence (20-day):** 1.1% (Positive - Short-term Increase)
*   **Expected Return:** -557.6%

**Analysis:**

*   The MRI suggests a high level of investment recommendation, seemingly contradicting other indicators.
*   The RSI indicates the stock is approaching oversold territory, which could signal a potential buying opportunity.
*   The PPO (Percentage Price Oscillator) is negative, suggesting a downward trend in price momentum.
*   Despite the negative expected return, the hybrid signal recommends a full investment.
*   The 20-day relative divergence suggests a short-term upward movement.
*   The Last Market price decrease suggests the recent price decline.
*   The very negative expected return is a significant concern.

**4. Recent News & Events:**

*   The news headlines are a mix of general market commentary and specific news about Merck. Key items include:
    *   Discussion of Merck as a dividend stock.
    *   Analysis of Merck's prospects.
    *   Merck Manuals sharing information on COPD.

**Analysis:** The news articles present a mixed picture. Some articles suggest potential investment opportunities, while others highlight challenges.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean of 2.00)
*   **Opinions:** 25 analysts
*   **Target Price:** Average: 101.60, High: 141.00, Low: 82.00

**Analysis:** Analyst consensus is generally positive with a "Buy" rating.  The average target price suggests significant upside potential from the current price. However, there is a wide range in target prices, indicating uncertainty among analysts. There were no recent rating changes listed.

**5. Recent Earnings:**

| 날짜        | EPS   | 매출       |
|-------------|-------|------------|
| 2025-08-05  | 1.76  | 15.81 B$   |
| 2025-05-02  | 2.01  | 15.53 B$   |
| 2024-11-06  | 1.25  | 16.66 B$   |
| 2024-08-05  | 2.15  | 16.11 B$   |
| 2025-08-05  | 2.15  | 16.11 B$   |

**Analysis:**  Earnings per share (EPS) and revenue have fluctuated. The most recent EPS of 1.76 is lower than the previous quarter.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $15.81B    | 77.50%        |
| 2025-03-31   | $15.53B    | 77.98%        |
| 2024-12-31   | $15.62B    | 75.50%        |
| 2024-09-30   | $16.66B    | 75.51%        |
| 2024-06-30   | $16.11B    | 76.76%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-06-30   | $48.99B    | 9.04%  |
| 2025-03-31   | $48.34B    | 10.51% |
| 2024-12-31   | $46.31B    | 8.08%  |
| 2024-09-30   | $44.50B    | 7.09%  |
| 2024-06-30   | $43.58B    | 12.52% |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable, with some quarterly variations.
*   **Profit Margin:**  Profit margins are high and relatively consistent, indicating strong profitability.
*   **Equity:** Equity has been increasing, showing growth in the company's net assets.
*   **ROE:** Return on Equity (ROE) fluctuates, indicating variations in the company's efficiency in generating profits from equity.

**7. Overall Assessment:**

Merck & Co Inc (MRK) presents a mixed investment picture. While analysts have a generally "Buy" rating, the stock has significantly underperformed the S&P 500. The stock price is trending downwards, and the negative expected return is a major concern. However, the high profit margins, stable revenue, and approaching oversold RSI could signal a potential turnaround opportunity.

**Key Considerations:**

*   **Underperformance:**  The large deviation from the S&P 500 needs to be addressed. What are the reasons for this underperformance?
*   **Expected Return:** The very negative expected return requires investigation. This may reflect recent losses, sector issues, or specific company challenges.
*   **Analyst Optimism vs. Reality:**  While analysts are optimistic, the technical indicators and performance suggest caution.
*   **News:** Focus on news related to Merck's specific pipeline, products, and strategic initiatives.

**In conclusion, a thorough understanding of the reasons behind the negative expected return and the underperformance relative to the S&P 500 is crucial before making an investment decision. Further research is recommended to understand the underlying causes and potential catalysts for a turnaround.**
